In conclusion, this was the first study supporting an association between miR-483-3p, FAM171B and OXA resistance in CRC, thus further efforts are required to test the effect of miR-483-3p adjuvant treatment in clinical use combined with OXA for cancer patients [253]. Here, FAM171B is linked to colorectal carcinoma.